环球生命科学研究,Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial - The Lancet Oncology,Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC - Journal of Thoracic Oncology,KN- 048 Mono OS - MConnect GCC,Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | New England Journal of Medicine,